Holen Sie sich die Stockscreener-App
55.90
4.44%
-2.60
Handel nachbörslich:
56.06
0.16
+0.29%
Schlusskurs vom Vortag:
$58.50
Offen:
$58.45
24-Stunden-Volumen:
1.77M
Relative Volume:
0.82
Marktkapitalisierung:
$7.90B
Einnahmen:
$622.01M
Nettoeinkommen (Verlust:
$-271.86M
KGV:
-26.02
EPS:
-2.1484
Netto-Cashflow:
$-45.87M
1W Leistung:
-10.92%
1M Leistung:
-15.03%
6M Leistung:
-17.77%
1J Leistung:
+43.44%
1-Tages-Spanne:
$55.83
$58.45
1-Wochen-Bereich:
$55.83
$62.50
52-Wochen-Spanne:
$36.57
$95.49
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Firmenname
Arrowhead Pharmaceuticals Inc
Sektor
Branche
Telefon
626-696-4702
Adresse
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
55.90 | 7.90B | 622.01M | -271.86M | -45.87M | -2.1484 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-15 | Fortgesetzt | UBS | Buy |
| 2026-09-24 | Fortgesetzt | Goldman | Neutral |
| 2026-09-08 | Eingeleitet | Citigroup | Buy |
| 2026-07-14 | Eingeleitet | Stifel | Buy |
| 2026-05-01 | Eingeleitet | JP Morgan | Overweight |
| 2026-04-21 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Eingeleitet | Goldman | Neutral |
| 2023-12-04 | Eingeleitet | BofA Securities | Buy |
| 2023-09-19 | Eingeleitet | Citigroup | Neutral |
| 2023-07-21 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-12 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-12 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Fortgesetzt | Goldman | Buy |
| 2021-08-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-19 | Eingeleitet | Citigroup | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-05-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Eingeleitet | Goldman | Neutral |
| 2020-01-21 | Eingeleitet | SVB Leerink | Underperform |
| 2019-12-13 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-29 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-27 | Bestätigt | B. Riley FBR | Buy |
| 2019-11-25 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-10-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-09-07 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-08-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo Finance
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock forecasts - Yahoo Finance Singapore
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock forecasts - Yahoo Finance UK
ARWR6277444 Bond Profile: Coupon and Redemption - TradingView
Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher - Seeking Alpha
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo Finance
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo Finance
Homozygous Familial Hypercholesterolemia (HoFH)7MM Market, Epidemiology, and Forecast2036 | RNAi and Targeted Therapies Expand Uptake and Investment Opportunities - GlobeNewswire Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock forecasts - au.finance.yahoo.com
Long term debt to total equity ratio of Arrowhead Pharmaceuticals, Inc. – HAN:HDP1 - TradingView
ETFs Investing in Arrowhead Pharmaceuticals, Inc. Stocks - TradingView
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies - Business Wire
Interim results from an experimental Alzheimer’s drug study will be presented Oct. 14. - Stock Titan
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies - Yahoo Finance
Arrowhead Achieves Clinical Validation for New Drug Platform - finance.yahoo.com
One experimental therapy silenced two genes at once. More results will follow at a medical congress. - Stock Titan
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia - Arrowhead Pharmaceuticals, Inc.
How Investors May Respond To Arrowhead Stock Phase 3 Trial Results - webull.com
Avoiding Lag: Real-Time Signals in (ARWR) Movement - Stock Traders Daily
ARWR Looks 63.8% Overvalued on GF Value™ - GuruFocus
Arrowhead Pharmaceuticals, Inc. (ARWR) Latest Stock News & Headlines - finance.yahoo.com
ARWR Initiated Coverage by Citigroup -- Price Target Announced a - GuruFocus
ARWR: SHASTA-3 and SHASTA-4 Data Presented at ESC 2026 - Yahoo Finance
Citigroup Initiates Arrowhead Pharmaceuticals at Buy With $108 Price Target - finance.yahoo.com
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million - Yahoo Finance
Arrowhead Pharmaceuticals Inc. (ARWR) Key Financial Ratios – Valuation, Profitability & More - Value Research
Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label? - Yahoo Finance
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences - Yahoo Finance
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe HypertriglyceridemiaSlideshow (NASDAQ:ARWR) 2026-09-02 - Seeking Alpha
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at European Society of Cardiology (ESC) Congress 2026Slideshow (NASDAQ:ARWR) 2026-09-02 - Seeking Alpha
ARWR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $120 - GuruFocus
Is Arrowhead Pharmaceuticals (ARWR) Undervalued As SHASTA 3 And SHASTA 4 Data Impress? - Yahoo Finance
Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says - marketscreener.com
Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials - Yahoo Finance
Stifel reiterates Buy rating on Arrowhead Pharma stock at $104 - Investing.com
Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split - biospace.com
Arrowhead Pharmaceuticals' Plozasiran Meets Endpoints in Studies of Patients With Severe Hypertriglyceridemia - marketscreener.com
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia - Investing News Network
Arrowhead’s plozasiran cuts pancreatitis events in Phase 3 studies (ARWR:NASDAQ) - Seeking Alpha
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia - Arrowhead Pharmaceuticals, Inc.
Could Arrowhead Pharmaceuticals (ARWR)’s Plozasiran Become the Catalyst for a Major Stock Re-rating? - finance.yahoo.com
Arrowhead Pharmaceuticals Inc. (ARWR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress - Business Wire
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress - Arrowhead Pharmaceuticals, Inc.
Don't Ignore The Insider Selling In Arrowhead Pharmaceuticals - Moomoo
Arrowhead Pharmaceuticals director sells $173,920 in stock - Investing.com
Arrowhead Pharmaceuticals (ARWR) Director Adeoye Olukotun Sells 2,000 Shares - GuruFocus
Arrowhead (ARWR) Stock: Slides 3.28% to $86.47 in the Latest Reading; Technical Setup: the $82.15 to $90.79 Range Remains in Focus at the CloseHigh Dividend Factor - Vinanet
Finanzdaten der Arrowhead Pharmaceuticals Inc-Aktie (ARWR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arrowhead Pharmaceuticals Inc-Aktie (ARWR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| PERRY MICHAEL S | Director |
Aug 18 '26 |
Sale |
87.30 |
11,600 |
1,012,680 |
111,459 |
| Adeoye Olukotun | Director |
Aug 18 '26 |
Proposed Sale |
86.94 |
2,000 |
173,876 |
0 |
| Michael Perry | Director |
Aug 18 '26 |
Proposed Sale |
87.26 |
11,600 |
1,012,172 |
0 |
| Lu Hongbo | Director |
May 12 '26 |
Sale |
76.88 |
2,970 |
228,334 |
52,012 |
| Hongbo Lu | Officer |
May 12 '26 |
Proposed Sale |
76.87 |
2,970 |
228,299 |
0 |
| James Hamilton | Officer |
Apr 23 '26 |
Proposed Sale |
75.00 |
10,000 |
749,998 |
0 |
| Hamilton James C | Chief Medical Officer |
Apr 23 '26 |
Sale |
75.00 |
10,000 |
750,000 |
226,958 |
| Apel Daniel Joseph | Chief Financial Officer |
Apr 22 '26 |
Sale |
71.35 |
13,095 |
934,285 |
162,905 |
| Daniel Apel | Officer |
Apr 22 '26 |
Proposed Sale |
71.34 |
13,095 |
934,206 |
0 |
| Hamilton James C | Chief Medical Officer |
Mar 05 '26 |
Sale |
64.19 |
10,000 |
641,900 |
236,958 |
4.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):